Ratings Bayer CropScience Limited NSE India S.E.

Equities

BAYERCROP

INE462A01022

Market Closed - NSE India S.E. 07:43:46 2024-04-26 am EDT 5-day change 1st Jan Change
5,525 INR -0.86% Intraday chart for Bayer CropScience Limited -3.35% -0.48%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The group's high margin levels account for strong profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.11 times its estimated earnings per share for the ongoing year.
  • The company's enterprise value to sales, at 4.41 times its current sales, is high.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.

Ratings chart - Surperformance

Sector: Agricultural Chemicals

1st Jan change Capi. Investor Rating ESG Refinitiv
-0.48% 2.98B -
-.--% 11.15B -
B+
-7.28% 7.3B
A
+7.47% 6.87B
B-
-3.91% 5.91B
B+
-6.14% 5.54B
B
-10.44% 5.6B -
C-
+31.35% 5.19B
B-
-13.45% 4.58B
C+
+17.77% 4.4B - -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality